September 20, 2014 9:34 PM ET


Company Overview of Reata Pharmaceuticals, Inc.

Company Overview

Reata Pharmaceuticals, Inc. focuses on developing medicines for difficult-to-treat diseases. The company develops drugs with potent transcription-regulating activity called antioxidant inflammation modulators, which are potent activators of the biological transcription factor Nrf2 that controls the body's production of antioxidative and cytoprotective molecules, as well as protects against diseases involving inflammation and oxidative stress. Its product pipeline comprises drugs under development for treating immuno-oncology and ophthalmology problems, cancer supportive care, cardiovascular problems, bioenergetic diseases, and autoimmune and respiratory problems. Reata Pharmaceuticals, Inc. ...

2801 Gateway Drive

Suite 150

Irving, TX 75063

United States

Founded in 2002





Key Executives for Reata Pharmaceuticals, Inc.

Age: 60
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Founding Scientist and Scientific Advisor
Compensation as of Fiscal Year 2014.

Reata Pharmaceuticals, Inc. Key Developments

Reata Enrolls First Patient in the PRIMROSE Study, a Phase 2 Study Examining RTA 408 in Breast Cancer Patients at Risk for Radiation Dermatitis

Reata announced the enrollment of the first patient in a Phase 2 dose-ranging study examining the safety, tolerability, and efficacy of RTA 408 Lotion (3% and 0.5%) versus vehicle for the prevention and treatment of radiation dermatitis in breast cancer patients for whom radiation therapy (RT) is recommended. PRIMROSE (A Randomized Double-Blind, Vehicle-Controlled, Parallel-Group Phase 2 Study of the Efficacy Safety, Pharmacokinetics, and Pharmacodynamics of RTA 408 Lotion in the Treatment of Patients at Risk for Radiation Dermatitis) is a multi-center study in approximately 180 patients. The primary efficacy endpoint is the time-averaged effect on radiation dermatitis severity. Radiation dermatitis is a complication experienced by a majority of patients receiving radiation therapy for cancer. RT can damage the cellular structures in the skin and cause pain, ulceration, necrosis, and fibrosis of exposed skin tissues. Radiation dermatitis usually manifests within one to four weeks after initiation of RT and can result in delays in or failure to complete RT, limiting the dose effect of RT, which can negatively affect treatment outcomes. There are currently no approved agents for the prevention of radiation-induced dermatitis.

Reata Pharmaceuticals Discontinues Phase 3 Clinical Study, BEACON

On October 17, 2012 Reata Pharmaceuticals, Inc. informed Abbott that it is discontinuing the Phase 3 clinical study, known as BEACON, designed to evaluate bardoxolone methyl in patients with advanced (stage 4) chronic kidney disease (CKD) and type 2 diabetes. The discontinuation is based on a recommendation from the study's Independent Data Monitoring Committee (IDMC) regarding safety concerns due to excess serious adverse events and mortality in the bardoxolone methyl arm. Regulatory Agencies have been notified of this decision, and study sites and study participants are currently being informed. Reata and Abbott will closely examine the data from this study to determine whether there is an appropriate path forward for the development of bardoxolone methyl in chronic kidney disease or other indications.

Similar Private Companies By Industry

Company Name Region
Kibow Biotech, Inc. United States
Aurora Biotechnologies, Inc. United States
Ablitech, Inc. United States
Impel Neuropharma Inc. United States
Zirus, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Reata Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at